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Abstract 
Background: T lymphocytes are highly dynamic elements of the immune system with a tightly regulated migration. 
T cell‑based transfer therapies are promising therapeutic approaches which in vivo efficacy is often limited by the 
small proportion of administered cells that reaches the region of interest. Manipulating T cell localisation to improve 
specific targeting will increase the effectiveness of these therapies. Nanotechnology has been successfully used for 
localized release of drugs and biomolecules. In particular, magnetic nanoparticles (MNPs) loaded with biomolecules 
can be specifically targeted to a location by an external magnetic field (EMF). The present work studies whether MNP‑
loaded T cells could be targeted and retained in vitro and in vivo at a site of interest with an EMF.
Results: T cells were unable to internalize the different MNPs used in this study, which remained in close associa‑
tion with the cell membrane. T cells loaded with an appropriate MNP concentration were attracted to an EMF and 
retained in an in vitro capillary flow‑system. MNP‑loaded T cells were also magnetically retained in the lymph nodes 
after adoptive transfer in in vivo models. This enhanced in vivo retention was in part due to the EMF application and 
to a reduced circulating cell speed within the organ. This combined use of MNPs and EMFs did not alter T cell viability 
or function.
Conclusions: These studies reveal a promising approach to favour cell retention that could be implemented to 
improve cell‑based therapy.
Keywords: Cell‑based therapy, T cell, Magnetic nanoparticle, Magnetic retention, Lymph node
© The Author(s) 2019. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creat iveco mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creat iveco mmons .org/
publi cdoma in/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Open Access
Journal of Nanobiotechnology
*Correspondence:  dfbarber@cnb.csic.es 
1 Department of Immunology and Oncology, and NanoBiomedicine 
Initiative, Centro Nacional de Biotecnología (CNB)‑CSIC, Darwin 3, 
Cantoblanco 28049, Madrid, Spain
Full list of author information is available at the end of the article
Background
Immunotherapy has re-emerged as a promising thera-
peutic tool in recent years [1]. The idea of specifically 
modulating the immune response represents an attrac-
tive approach to restore or enhance the immune sys-
tem’s ability to fight cancer or control autoimmune 
diseases. In particular, immune cell-based thera-
pies, which are based on the use of the patient’s own 
cells after in  vitro expansion and/or modification, 
are currently one of the most appealing strategies in 
this field [2, 3]. This approach can be applied to treat 
either cancer [4, 5] or autoimmunity [6–8]. The clinical 
response rates that these strategies elicit are nonethe-
less strongly correlated to the number of transferred 
cells that reach the desired region. As such, one of the 
main limitations of cell-based therapies is the disper-
sion of the in  vivo-administered cells which results 
in only a small proportion of cells reaching the site of 
interest [9]. There is therefore a clear need to develop 
new strategies that promote specific cell infiltration, 
accumulation and survival in specific tissues so that 
they can exert their function effectively.
Nanotechnological approaches can offer a solu-
tion, as they can increase treatment effectiveness by 
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concentrating therapeutic molecules in the required 
region. Nanoparticle-based drug delivery systems can 
access difficult-to-reach sites because of their small size. 
They can be directed by active or passive strategies based 
on the nanomaterial physical and chemical properties 
and/or through addition of targeting moieties in the nan-
oparticle coating [10]. One promising active approach 
is based on superparamagnetic iron oxide nanoparti-
cles, which can be localized precisely in the desired area 
by applying an external magnetic field (EMF) [11]. This 
approach could promote specific cell accumulation and 
thereby improve the efficacy of cell transfer therapies. 
Non-lymphoid cells loaded with these magnetic nano-
particles (MNPs) can be inoculated systemically and 
attracted to a target tissue in mice by the application of 
an EMF [12–17]. These studies focused mainly on enrich-
ing stem cells, mesenchymal cells, macrophages or den-
dritic cells to control tissue injury and immune disorders. 
Studies using in vivo delivery of magnetically guided lym-
phoid cells to treat cancer and autoimmunity are very 
limited [18] and this field remains vastly unexplored. The 
manipulation of highly motile effector lymphoid cells 
such as T or natural killer (NK) cells to target and accu-
mulate them to a specific region such as lymph nodes 
(LNs) or solid tumours could be a promising approach to 
enhance their activity in the desired area.
In this work, we focus on T lymphocytes, an essential 
effector cell of the adaptive immune system, which con-
tinuous circulation is very dynamic compared to other 
immune cells such as dendritic cells or macrophages. 
During an immune response, T cells need to interact with 
other cells and detect antigens in different contexts and 
tissues [19]. T cell migration, which is tightly regulated by 
multiple factors, such as cellular expression of selectins 
and chemokine receptors and interaction with other cells 
in secondary lymphoid organs (SLOs), is critical for the 
development of effective T cell responses [20, 21]. T cells 
circulate through lymphoid and target organs where they 
can search for their cognate antigen either on the surface 
of antigen-presenting cells (APCs) in lymphoid organs 
or on target cells in peripheral organs. Initial T cell acti-
vation steps occur in SLOs such as the LNs, where the 
tissue organization allows murine primary T cells to 
encounter their cognate antigen on APCs coming from 
different tissues and become activated. Once activated, 
these antigen-experienced T cells scan peripheral tissues 
to find and eliminate their antigen [22, 23]. Manipulating 
T cells to target specific locations could therefore be an 
interesting strategy to promote for instance their accu-
mulation in the SLOs during priming and activation to 
enhance the immune response, or to favour their reten-
tion in the target tissue once activated. MNP-loading of 
T cells could thus be used for these targeting purposes as 
long as T cell function and interaction with chemokines, 
adhesion molecules and other cell types is not impaired 
by the treatment.
In this study, we evaluated the possibility that MNPs 
could be used as a platform to magnetically guide T cells 
to a region of interest. We assess T cell migration func-
tionality after MNP treatment as well as their in vitro and 
in vivo manipulation to a target site through the applica-
tion of an EMF.
Methods
Iron oxide core synthesis
Iron oxide cores were prepared by following the Massart 
coprecipitation protocol [24]. Briefly, 445 ml of a mixture 
of  FeCl3·6H2O (0.09  mol) and  FeCl2·4H2O (0.054  mol) 
were added to 75  ml of  NH4OH (25%). This addition 
was performed slowly and under vigorous stirring. The 
mixture was heated at 90 °C for 90 min to prepare nano-
particles of approximately 12 nm in diameter. After that, 
the sample was washed three times with distilled water 
by magnetic decantation. To oxidize magnetite to magh-
emite and activate surface for subsequent steps, the pre-
cipitate was treated with 300  ml of  HNO3 (2  M) under 
stirring for 15  min. Then, nitric acid was removed by 
magnetic decantation, and 75 ml of Fe(NO3)3 (1 M) and 
130  ml of water were added over the preparation. The 
mixture was heated up to boiling temperature and stirred 
for 30 min. The particles were then cooled to room tem-
perature and, by magnetic decantation, the supernatant 
was substituted by 300 ml of  HNO3 (2 M) and stirred for 
15 min. Finally, they were washed three times with ace-
tone and dispersed in distilled water. A rotary evaporator 
was used to remove any acetone waste and concentrate 
the sample.
MNP surface coating
Iron oxide cores were coated with dimercaptosuccinic 
acid (DMSA), 3-aminopropyl-triethoxysilane (APS) 
or dextran (6  kDa) following procedures previously 
described [25]. Briefly, for DMSA coating (DMSA-
MNPs), 14.7  mg (0.08  mmol) of DMSA were added to 
a suspension of 30  ml of the iron oxide cores (0.05  M) 
under stirring at pH 3. After this, the pH was increased to 
11 and the sample was sonicated for 20 min. After coat-
ing, this suspension was dialyzed for 2  days and finally; 
the pH was adjusted to 7. For APS coating (APS-MNPs), 
1.17  ml (0.005  mol) of APS was added very slowly to a 
mixture of 10  ml of the iron oxide cores (28  g  Fe2O3 
per l) and 10  ml of methanol under vigorous stirring 
for 12–16  h. Methanol was eliminated from the mix-
ture using a rotary evaporator. The sample was then 
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washed three times with a mixture of acetone/water 
(70/30) and redispersed in 10  ml of distilled water. The 
pH was decreased to 3 and the sample was sonicated for 
1 h. Finally, the pH was adjusted to 7 and sonicated for 
10  min. For Dextran coating (DEXT-MNPs), the iron 
oxide core dispersion [600 mg of  Fe2O3 in 4.8 ml NaOH 
(0.8 M)] was added dropwise into a solution of 600 mg of 
dextran (6 kD) in 7.5 ml NaOH (0.5 M) under sonication. 
The mixture was sonicated for 6  h under refrigeration. 
After coating, this suspension was dialyzed for 3 days and 
finally; the pH was adjusted to 7.
MNP characterization
For TEM analyses, a drop of a dilute MNP suspension 
was placed on a carbon-coated copper grid and the sol-
vent allowed to dry at room temperature. Images were 
acquired with a JEOL JEM 1011 transmission electron 
microscope with Gatan ES1000Ww camera. MNP size, 
shape and distribution were determined using TEM 
images and ImageJ software. For hydrodynamic size and 
Z-potential determination, we analysed a suspension of 
MNPs in water or in 0.01 M  KNO3 solution, respectively. 
Dynamic light scattering (DLS) for colloidal characteriza-
tion was carried out using a Nano Sizer ZS (Malvern).
Coating presence on MNP surface was determined 
from FTIR spectra, recorded between 4000 and 250 cm−1 
on a Bruker (USA) IFS 66V-S spectrometer and a Nicolet 
FT-IR 20SXC (Thermo Scientific, USA). Thermal analysis 
was performed to quantify the amount of coating mol-
ecules on the MNP surface. Simultaneous thermogravi-
metric (TG) and differential thermal analysis (DTA) were 
performed on a Seiko TG/DTA 320U thermobalance 
(Seiko Instruments, Japan). Samples were heated from 
room temperature to 900  °C at 10  °C/min under an air-
flow of 100 ml/min. Iron determination was carried out 
in an inductively coupled plasma-optical emission spec-
trometry (ICP-OES) OPTIME 2100DV [Perkin Elmer 
(USA)] apparatus after acid digestion. For the magnetic 
characterization, liquid samples were frozen and dried 
overnight in a LyoQuest freeze dryer (Telstar, Spain). 
The resulting solid sample was compacted into gela-
tine capsules for magnetic characterization. Hysteresis 
loops with a maximum field of 5 T were measured in a 
Vibrating Sample Magnetometer (MLVSM9, MagLab 
9T, Oxford Instruments, UK). AC magnetic susceptibil-
ity measurements were performed in a Quantum Design 
(USA) MPMS-XL SQUID magnetometer with magnetic 
field amplitude of 0.41 mT and a frequency of 11 Hz in 
the temperature range between 2 and 300 K. Endotoxin 
levels in MNP preparations were measured using a com-
mercial LAL chromogenic assay (Lonza) according to the 
manufacturer’s instructions.
Cell culture
The human cell line Jurkat (ATCC: TIB-152) and the 
murine cell line RAW264.7 (ATCC: TIB-71) were cul-
tured in DMEM with 10% FBS, 2 mM l-glutamine, 1 mM 
sodium pyruvate, 50 µM 2-mercaptoethanol and 100 U/
ml penicillin/streptomycin (P/S) in standard culture con-
ditions (37  °C, 5%  CO2, 90% relative humidity). Murine 
primary T cells were purified from spleen and LN cell 
suspensions obtained from C57BL/6 mice (Harlan Lab-
oratories) using the Mouse T cell Isolation kit (STEM-
CELL Technologies). After isolation, T cells were 90–95% 
 CD3+ by flow cytometry analysis and cultured in RPMI 
with 10% FBS, 2  mM  l-glutamine, 2-mercaptoethanol 
and 100 U/ml P/S in standard culture conditions (37  °C 
5%  CO2, 90% relative humidity).
MNP treatment
Jurkat and murine primary T cells were incubated with 
MNPs (150  µg Fe/ml) in a reduced volume at high cell 
density  (106 cells in 100  µl corresponding medium) for 
2 h in standard conditions.
Cell viability, MNP uptake and staining assays
Cell viability was analysed by two methods. In the 
AlamarBlue assay (Invitrogen), cells were cultured in 
a 96-well plate with different MNP concentrations for 
24 h and AlamarBlue was added to each well, incubated 
for 4 h and fluorescence was finally measured (530 nm 
excitation, 590 nm emission). Cell survival is expressed 
as the percentage of fluorescence of MNP-treated cells 
compared to untreated cells. For FITC-annexin V/pro-
pidium iodide staining, cells were processed using the 
Annexin V-PI apoptosis assay kit according to the man-
ufacturer’s protocol (Life Technologies) and analyzed 
by flow cytometry on a FC500 flow cytometer.
To quantify MNP uptake, cells  (107 cells/ml) were 
incubated with MNPs (150 µg Fe/ml) for 2 h in stand-
ard conditions, washed with PBS and digested for 1 h at 
90 °C sequentially with 1 ml  HNO3 63% and then, with 
1 ml  H2O2. Iron determination was performed by ICP-
OES as in MNP characterization.
Different microscopy techniques were used to deter-
mine MNP subcellular location. For iron staining, cells 
were washed with PBS after incubation with MNPs, 
fixed in paraformaldehyde (PFA) 4% (15  min), per-
meabilized with TritonX-100 (5  min), stained with an 
equal volume of HCl 4% and potassium ferrocyanide 
trihydrate 4% (Prussian blue, 20–30 min) and counter-
stained with neutral red 0.5% (1  min). Samples were 
washed with distilled water, air-dried and mounted 
using mounting medium (7.7% gelatine, 54% glycerol). 
Images were acquired on an Olympus IX70 inverted 
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bright field microscope with 63× or 100× oil-objec-
tives. For dark-field confocal microscopy, LysoTracker 
Red DND-99 (Life Technologies) was added to the 
media during the incubation with MNPs. Alexa Fluor 
647-wheat germ agglutinin (Life Technologies) was 
added during the last 15  min to the culture. Cells 
were then washed, fixed with PFA 4% (15  min), coun-
terstained with DAPI and mounted in Fluoromont-G 
(SouthernBiotec). Images were acquired with a 0.13 μm 
step with a confocal multispectral Leica TCS SP5 sys-
tem with a 63×/1.4 NA oil objective and 5× zoom. For 
dark-field acquisition of MNPs, the 488  nm laser light 
was used. ImageJ software was used for image analysis 
and orthogonal projections. For TEM microscopy, cells 
were fixed at RT in 2% glutaraldehyde, 1% tanic acid in 
0.4  M HEPES at PH 7.2, washed and resuspended in 
HEPES buffer. Samples were processed and included 
by the Transmission Electronic Microscopy Service at 
the National Center for Biotechnology (CNB-CSIC, 
Madrid, Spain). Images were acquired at different mag-
nifications with a JEOL JEM 1011 transmission electron 
microscope with Gatan ES1000Ww camera.
Real‑time metabolic analysis
Metabolic profiling of MNP-free and -loaded murine 
primary T cells was undertaken using a Seahorse XFp 
Extracellular Flux Analyser (Agilent Technologies) with 
the Agilent Seahorse XFp Cell Energy Phenotype Test Kit 
following the manufacturer’s protocol.
Calcium imaging assays
An 8-well μ-Slide (Ibidi) was coated with poly-lysine 
(Sigma) for 1  h at RT, washed 3 times with PBS and 
allowed to dry at 37  °C. Cells  (107 cells/ml) were incu-
bated with MNPs (150 µg Fe/ml) for 2 h in standard con-
ditions. Untreated and MNP-treated cells were washed 
with PBS and calcium starved for 3  h. After this, cells 
(2.5 × 106 cells/ml) were stained with Fluo-3 AM (3 µM, 
Invitrogen) for 30  min at 37  °C in rotation and washed 
with HBSS 1× (Gibco) 10% FBS without calcium. 
2.5 × 105 cells in 250 µl of HBSS 1× 10% FBS without cal-
cium were seeded per well and allowed to attach to the 
bottom of the poly-lysine coated slides for 5 min. Movies 
were acquired every 645  ms with a confocal multispec-
tral Leica TCS SP5 system with a 20× objective and 2× 
zoom. Cell images were first recorded without calcium 
or stimuli for 3 min and then, 50 µl HBSS 1× 10% FBS 
with 50  ng/ml phorbol 12-myristate 13-acetate (PMA) 
(Sigma), 5 µM ionomycin (Sigma) and 2 mM  CaCl2 were 
added and movies immediately acquired for 10  min. In 
some experiments, an 8 × 6  mm neodymium–boron–
iron (NdFeB) permanent magnet (Br: 1.45 T) was placed 
next to the well to study EMF effects. The appropriate 
unstained and/or unloaded controls were also per-
formed. LAS X Life Science Software (Leica) was used to 
analyse fluorescence fluctuation in cells due to calcium 
fluxes changes.
Mice
C57BL/6 mice purchased from Harlan and athymic nude 
mice purchased from Envigo were maintained in the 
CNB animal facility and handled according to the rec-
ommendations of the CNB-CSIC institutional Ethics 
Committee. C57BL/6-Tg(CAG-EGFP)131Osb/LeySopJ 
(“Ubi-GFP”) mice purchased from Jackson and C57BL/6 
mice purchased from Janvier were maintained in the 
Theodor Kocher Institute animal facility and handled 
according to the recommendations of the Cantonal Eth-
ics Committee. The procedures involving animal work at 
CNB-CSIC were approved by the Ethics Committee for 
Animal Experimentation at the CSIC and by the Divi-
sion of Animal Protection of the Comunidad de Madrid 
in compliance with national and European Union legisla-
tion. The procedures involving animal work at the Theo-
dor Kocher Institute, University of Bern were approved 
by the Cantonal Committee for Animal Experimentation 
and were conducted according to federal and cantonal 
guidelines.
Flow cytometry
Cells  (107 cells/ml) were incubated with MNPs (150  µg 
Fe/ml) for 2 h in standard conditions, washed with PBS 
and stained with fluorochrome-conjugated Abs against 
cell surface markers. For Jurkat cells, the following anti-
human antibodies were used: anti-CD62L (DREGC 56, 
Coulter), -CD11a (25.3.1, Immunotech), -CD45 (KC56 
(T-200), Beckamn C.) and -CD44 (G44-26, Pharmingen). 
For murine primary T cells, the following anti-mouse 
antibodies from Biolegend were used: anti-CD44 (IM7), 
-CD62L (Mel-14), -CD11a (M17/4), -CCR7 (4B12), -CD4 
(RMA-5) and -CD8 (53-6.7). CCR7 labelling was per-
formed at 37  °C for 30  min with biotinylated primary 
antibody followed by secondary staining with PE-conju-
gated streptavidin. Data were acquired on a FC500 flow 
cytometer or in Attune Nxt flow cytometer and analysed 
with FlowJo software.
Transwell migration assay
Jurkat or murine primary T cells  (107 cells/ml) were 
treated or left untreated with MNPs (150  µg Fe/ml) for 
2 h in standard conditions and washed with PBS. MNP-
treated and untreated cells were differentially labelled 
with PKH26 Red or PKH67 Green fluorescent cell linker 
kits (Sigma Aldrich). MNP-treated and untreated cells 
were alternatively stained in red or green in repeat exper-
iments to exclude dye labelling effects. MNP-treated 
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and untreated cells were mixed in a ratio 1:1 and seeded 
(5 × 105 cells in 0.1  ml) in each insert (Corning, 5  µm 
pore insert for Jurkat cells and 3 µm for murine T cells) 
in RPMI+ 2% FBS. To create a chemotactic gradient 
the recombinant human CXCL12 (10  nM, Peprotech) 
or the recombinant murine CCL21 (25  nM, Peprotech) 
was added to the lower chamber in Jurkat or murine T 
cells, respectively. Cells were allowed to migrate for 
16  h (Jurkat cells) or 2  h (murine T cells) after which 
lower chamber contents were collected, stained with 
fluorochrome-labeled Abs against CD8 (53-6.7) and CD4 
(RMA-5) in the case of murine T cells and cells were 
counted by flow cytometry, using a FC500 flow cytom-
eter, and analysed by FlowJo software. Cell migration 
was referred and normalized to an input well [without 
transwell (100% migration)]. For magnetic field-exposed 
transwell assays, an 8 × 6  mm NdFeB permanent mag-
net (Br: 1.45 T) was placed under the well, just below the 
pore insert.
Flow chamber assays
In vitro magnetic retention assays under flow conditions 
were performed in a modified channel slide (µ-Slide I 
Luer, 0.4  mm height, ibidi). This modification allowed 
the two-magnet system, specially designed for this assay, 
to be placed on the chamber and produce a homogene-
ous strong magnetic gradient on both sides of the chan-
nel. Jurkat or murine primary T cells  (107 cells/ml) were 
incubated or left untreated with different doses of MNPs 
(50, 100 and 150  µg Fe/ml) for 2  h in standard condi-
tions, washed with PBS and stained with calcein-AM 
(ThermoFisher) for 20 min at 37 °C in PBS with 0.5% FBS. 
Cells were then diluted in PBS with 0.5% FBS (2.5 × 105 
cells/ml) until use. Flow chamber set-up was mounted 
on an Olympus Inverted Microscope model IX71 con-
nected to an Imaging Station  cellR and in standard cul-
ture conditions (37  °C 5%  CO2, 90% relative humidity). 
PBS with 0.5% FBS was infused at high flow rate to fill 
the system. Cells were infused at 0.5 dyne/cm2 (≈ 100 μl/
min). Images were recorded every 1  s for 4  min. After 
the first 60 s, the two-magnet system was placed into the 
flow chamber and its effect recorded for the remaining 
time. IMARIS Software (Bitplane) was used to generate 
the movies and for cell motility tracking. Displacement in 
Y-axes (magnetic-field direction) was analysed.
Adoptive transfer and in vivo T cell homing
Jurkat or murine primary T cells from C57BL/6 mice, 
MNP-treated and untreated, were stained with CFSE 
(Invitrogen) and Dye eFluor 670 (Thermofisher) and 
cell mixtures (1:1, total  107 cells/100  µl) were injected 
intravenously into nude or C57BL/6 mice, respectively. 
Mice were sacrificed after 90 min or 24 h for Jurkat cell 
transfer, or 1 h for murine T cell transfer. Spleen, periph-
eral (inguinal and axillary) (PLN) and mesenteric LNs 
(MLN) were removed to obtain a single cell suspension, 
and fluorophore-labeled cells counted by flow cytom-
etry [FACSCalibur flow cytometer (BD)] and analysed by 
FlowJo Software.
For magnetic-targeted homing, an 8 × 6  mm NdFeB 
permanent magnet (Br: 1.45 T) was placed over one of 
the popliteal LNs for 30 and 90 min for Jurkat cells and 
20 min for murine T cells. In this case, axillary, inguinal 
and popliteal LNs from both sides were collected.
Selective plane illumination microscopy (SPIM)
A mixture of MNP-treated and untreated murine pri-
mary T cells  (107 cells/mouse, ratio 1:1), isolated from the 
LNs and spleen of Ubi-GFP mice, were inoculated intra-
venously into C57BL/6 mice and 20-min homing experi-
ments with an 8 × 6 mm NdFeB permanent magnet (Br: 
1.45 T) over one of the popliteal LNs was performed. 
Untreated cells were previously stained with CMTMR 
(5 µM, Molecular Probes) for 20 min at 37  °C to differ-
entiate them from the treated ones (only GFP-labelled). 
High endothelial venules (HEV) networks were labelled 
by intravenous injection of Alexa Fluor 633-conjugated 
MECA79 mAb (Nanotools) 10  min prior to sacrifice 
and LN harvest. At 20 min after T cell transfer, popliteal 
LNs were collected and fixed in PFA 4% for 24 h before 
removing adjacent fat tissue under a stereomicroscope. 
Cleaned LNs were mounted in 2% ultrapure low-melting 
agarose and were optically cleared following the CUBIC 
protocol [26]. After this, LNs were scanned using a multi-
spectral SPIM setup as described [27].
Two‑photon laser scanning microscopy (2PM) of popliteal 
LNs
To analyse the behaviour of MNP-treated T cells in the 
LNs, the right popliteal LN of recipient mice was surgi-
cally prepared as previously described [28]. One or two 
8 × 6 mm NdFeB permanent magnet (1.45 T) were placed 
as close as possible to the popliteal LN as showed in 
Fig. 9. Once prepared, a mixture of CMTMR- (5 µM) or 
CMAC- (20  µM) MNP-treated and untreated cells  (107 
cells/mouse, ratio 1:1) was intravenously injected and 
HEV networks were labelled by intravenous injection of 
Alexa Fluor 633-conjugated MECA79 mAb (Nanotools) 
just prior to recording. CMAC (CellTracker Blue) and 
CMTMR (CellTracker Orange) were both purchased 
from Molecular Probes. 2PM imaging was performed 
using a TrimScope 2PM system equipped with a fluores-
cence microscope (BX50WI; LaVision Biotec; Olympus) 
equipped with a 20× objective (NA 0.95; Olympus). (11–
15)-slice z stacks with 4-µm spacing of 250 × 250–µm 
field of views (FOVs) were acquired every 20 s for 30 min. 
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IMARIS Software was used to generate 4D movies and 
for cell motility tracking. The Chemotaxis and Migration 
tool from Ibidi was used to plot the cells’ paths and ana-
lyse their directionality.
Results
Synthesis and characterization of MNPs with different 
surface charges for T cell guidance
MNPs with almost spherical morphology were obtained 
by the coprecipitation method and subsequent acid 
treatment (Massart’s procedure). Transmission elec-
tronic microscopy (TEM) imaging showed that these 
magnetic nanoparticle cores were on average 12.5  nm 
in diameter (Fig.  1a). The polydispersity degree was 
approximately 20%, indicating they are in the mono-
dispersed range. MNPs were subsequently coated with 
dimercaptosuccinic acid (DMSA-MNPs), 3-amino-
propyl-triethoxysilane (APS-MNPs) or dextran 6  kDa 
(DEXT-MNPs). This range of coatings produced MNPs 
with different surface charge and hydrodynamic size. 
The average particle size core of the coated MNPs and 
their aggregation status were verified by TEM (Fig. 1b). 
Fourier-transform infrared spectroscopy (FTIR) was 
used to evaluate the nature of each coating and its asso-
ciation to the MNP surface (Fig.  1c). Coated MNPs 
showed characteristic IR bands at frequencies between 
1000 and 1400 cm−1 associated to C–O and C–C bonds 
due to polymer presence on MNP surface. Extra bands 
were detected, at 1625, 1400 and 1140 cm−1 for DMSA 
(corresponding to the carboxylic acid-iron bond and 
C=O bonds), at 1095 and 998  cm−1 for APS (corre-
sponding to the formation of Si–O-Fe and Si–O-Si 
bonds) and in the range between 1000 and 1500 cm−1 
and at 1400 cm−1 for dextran (due to C–O–C and C=O 
bonds and  CH2 and C–O–H deformations) [25, 29]. IR 
bands at 500–600  cm−1 were present in all cases, due 
to the Fe–O bond (Fig. 1c). The band at 1381 cm−1 in 
APS-MNP spectra is due to the presence of nitric acid 
employed during MNP oxidation and pH adjustment 
[30]. Magnetization measurements confirmed MNP 
magnetic properties (Fig. 1d).
MNP hydrodynamic size values and surface charge 
were measured by dynamic light scattering (DLS). 
DMSA-MNPs, APS-MNPs and DEXT-MNPs hydro-
dynamic sizes were 83  nm, 82  nm and 120  nm respec-
tively (Table 1). Coating quantification was performed by 
thermogravimetric (TG) analyses. The weight percent-
age of these coatings varied from 10% for DMSA-coated 
MNPs and APS-coated MNPs to approximately 38% for 
DEXT-coated MNPs (Table 1). Iron concentration in the 
MNP preparations was measured by inductively coupled 
plasma optical emission spectrometry (ICP-OES). Endo-
toxin levels were below 0.1 EU/ml for all MNP prepara-
tions (Table 1).
Fig. 1 Physico‑chemical characterization of MNPs. a TEM images of iron oxide cores prepared by co‑precipitation synthesis and MNP size 
distribution and Gaussian fitting. b TEM images of DMSA‑MNPs, APS‑MNPs and DEXT‑MNPs. c Fourier transformed infrared spectra for DMSA‑MNPs, 
APS‑MNPs and DEXT‑MNPs. d Magnetization curve for DMSA‑MNPs, APS‑MNPs and DEXT‑MNPs showing the superparamagnetic behaviour
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MNPs are not toxic and are mainly detected on T cell 
surface
To assess MNP effects on T cell we chose two T cell mod-
els: the human T cell line Jurkat and murine primary T cells 
isolated from C57BL/6 mice. To examine nanoparticle tox-
icity, we first analysed cell survival after MNP incubation 
using different assays. MNP treatment did not affect Jurkat 
and murine T cells viability in AlamarBlue assays (Fig. 2a, 
b). Indeed, MNP-treated T cells often showed greater 
fluorescence readings in the AlamarBlue assays, indicat-
ing a slight increase in the mitochondrial metabolism of 
these cells. Similarly, no statistically significant differences 
in apoptosis induction were detected by annexin V-FITC/
PI staining, even at MNP concentrations of 150 μg Fe/ml 
(Fig.  2c, d). Preliminary analysis of the metabolic pheno-
type of MNP-treated cells using the Seahorse extracellular 
flux analyser technology showed enhanced mitochondrial 
respiration and glycolysis (Additional file 1: Fig. S1).
To analyse how the three types of MNPs interacted 
with Jurkat and murine T cells, we first evaluated the 
capacity of these cells to associate with these MNPs after 
co-incubation. Optimal MNP association to T cells was 
obtained after 2-h incubation in a reduced volume. ICP 
measurements showed that both cell types were able 
to better associate with APS-MNPs than with DMSA-
MNPs or DEXT-MNPs (Fig. 2e, f ). Moreover, MNP asso-
ciation was higher in Jurkat cells than in murine T cells. 
Due to its high association to T cells, APS-MNPs thus 
appear as the preferred candidate to study MNP-medi-
ated retention of these cells.
We next studied MNP subcellular localization in 
these cells using different approaches. Pearls staining 
and confocal microscopy showed that MNPs, regard-
less of their polymeric coating, were mainly associ-
ated with the cell membrane (Fig. 3a, b). These results 
were confirmed by TEM (Fig.  3c). Most of the MNPs 
remain in the periphery of the cells, probably associ-
ated though electrostatic interactions with the mem-
brane. TEM images at higher magnification (Fig.  4) 
confirmed the close interaction between the different 
MNPs and the cell membrane. APS-MNPs were those 
that seem to associate more with the surface of Jurkat 
and murine T cells, covering a larger cell membrane 
area, in line with the previous iron ICP measurements. 
TEM microscopy with murine T cells also revealed an 
increase in the number of mitochondria after MNP 
treatment, supporting the enhanced metabolism seen 
in previous assays.
MNPs did not affect the expression of specific T cell 
markers but slightly impaired chemotactic response
To check whether MNP association with T cells affected 
their effector functions, we first analysed by flow 
cytometry the expression levels of several important T 
cell surface markers. In Jurkat cells the expression of 
the adhesion markers CD62L and CD44, the integrin 
CD11a and the general leukocyte marker CD45 was 
evaluated (Fig.  5a). In murine T cells we analysed the 
expression of CD62L, CD44, CD11a and the chemokine 
receptor CCR7 (Fig. 5b). No differences were observed 
in the expression levels of these markers in Jurkat or in 
murine T cells when treated with APS-MNPs.
In order to effectively play their role in immune sur-
veillance and in the body’s immune response, lym-
phocytes need to respond to chemotactic factors 
that allow them to enter and exit specific lymphatic 
organs and tissues [31, 32]. We therefore measured the 
response of MNP-loaded T cells to a chemokine gradi-
ent using transwell assay systems. MNP loading slightly 
impaired Jurkat cell migration in response to a CXCL12 
chemokine gradient (Fig. 5c). A similar trend was also 
observed with primary murine T cells, although this 
difference was not statistically significant (Fig. 5d). This 
migratory defect was nonetheless corrected when a 
magnetic field was applied in the same direction as the 
biological gradient, more notably for Jurkat and  CD4+ 
T cells (Fig. 5c, d). The application of an EMF probably 
facilitated the migration of MNP-loaded cells strug-
gling to respond to the chemotactic gradient alone.
Magnetic fields enhanced in vitro T cell retention in flow 
conditions
To evaluate the capacity of a magnetic field to retain MNP-
loaded T cells in hemodynamic conditions we analyse 
whether these cells were attracted to magnets in vitro in a 
dynamic flow system. Flow chambers were modified so that 
a two magnet system that exerts a homogenous and strong 
magnetic gradient [33, 34] could be applied at the cell flow 
Table 1 Summary of the main characteristics of DMSA-MNPs, APS-MNPs and DEXT-MNPs
MNPs Coating Core 
diameter 
(nm)
Hydrodynamic 
diameter (nm)
Z‑potential (mV) Coating (%) Endotoxin 
level (EU/
ml)
DMSA‑MNP Dimercaptosuccinic acid 12.5 83 − 34 10 < 0.1
APS‑MNP 3‑Aminopropyl‑triethoxysilane 12.5 82 + 38 10 < 0.1
DEXT‑MNP Dextran 6 kDa 12.5 119 − 2 38 < 0.1
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level (Fig. 6a). Cell retention was analysed by changing the 
MNP doses as well as the magnetic force used (Fig. 6b).
MNP-free cells only moved in the flow direction, as 
shown in the movie (Additional file 2: Movie S1), whereas 
cells loaded with 150  µg/ml APS-MNPs start mov-
ing towards the magnet when it was applied to the flow 
chamber, as shown in the movie (Additional file 3: Movie 
S2). T cells needed a minimal amount of MNP (> 5  pg 
Fe/cell in our setting) for the magnetic field produced by 
the 1.35 T magnets to start retaining them (Additional 
file  1: Fig. S2). As the amount of cell-associated MNPs 
increased so did the cell retention by the magnetic field 
(Additional file  1: Fig. S2; Fig.  6c, d). This cell accumu-
lation was also augmented when a stronger magnet 
Fig. 2 MNP toxicity and association to Jurkat and murine primary T cells. a Jurkat and b murine T cell viability after MNP treatment measured by 
AlamarBlue assays. Annexin‑V/PI analysis by flow cytometry of c Jurkat and d murine T cells after MNP treatment. e Jurkat and f murine T cell iron 
association after MNP treatment. Data (mean ± SD) are representative of three independent experiments in all analyses
Fig. 3 MNP subcellular localisation in Jurkat and murine primary T cells. a Representative images of Jurkat and murine T cells after MNP treatment 
acquired by confocal microscopy [cell membrane (red), MNPs (gray) and nuclei (blue)] (scale bar = 10 μm). ImageJ software was used for orthogonal 
projections. b Perls’ Prussian blue staining and neutral red counterstaining of Jurkat and murine T cells after MNP treatment (scale bar = 10 μm). c 
Representative TEM images of Jurkat and murine T cells after MNP treatment. Whole cells (top panel pictures) were imaged as well as more detailed 
cell parts (bottom panel pictures) to better illustrate interactions between MNPs and cell surface. Arrowheads indicate MNP aggregates attached to 
the cell surface
(See figure on next page.)
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(magnet B) was applied (Fig.  6c, d). Furthermore, cells 
were immobilised at the chamber wall near the magnet 
while attached (Fig.  6e) but resume following the flow 
direction once the magnet was removed. Similar results 
were obtained with both cell types, although magnetic 
retention in Jurkat cells was higher than in murine T cells 
since they associated with more MNPs as seen in ICP 
measurements.
T cell in vivo accumulation in the LNs was promoted 
by MNP loading and enhanced by localized EMFs 
application
Since T cells are continuously migrating into SLOs, 
such as LNs to maintain immune homeostasis [35], we 
decided to test, as a proof of concept for in vivo magnetic 
retention, whether the application of an EMF could affect 
the homing and retention of MNP loaded-T cells to a 
Fig. 4 MNP association with the cell membrane of Jurkat and murine primary T cells. Representative TEM images of Jurkat and murine T cells after 
MNP treatment. Highly detailed images showing the interaction between MNPs and cell surface (magnification 150–×200). Arrowheads indicate 
MNP aggregates attached to the cell surface. Scale bar: 50 nm
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specific LN. MNP concentration (150 µg/ml APS-MNPs) 
and magnetic force [8 × 6 mm NdFeB permanent magnet 
(Br: 1.45 T)] used in in  vivo studies were based on the 
optimal results obtained in flow chamber assays (Fig. 6c, 
d). A combination (ratio 1:1) of MNP-free and -loaded 
cells (Jurkat or murine T cells) was differentially labelled 
with dye Efluor 670 (red) or CFSE (green), to eliminate 
possible unspecific retention effects due to dye loading. 
Then,  107 cells per mouse were intravenously inoculated 
in 5–6  weeks old mice (nude mice for Jurkat cells and 
C57BL/6 for murine T cells) and allowed to distribute in 
the organism. Mice were sacrificed at different timepoints 
post-adoptive transfer and representative lymphoid 
organs collected (axillary, inguinal, popliteal, mesenteric 
LNs and spleen depending on the experiments). In some 
experiments, an EMF was applied over a popliteal LN to 
promote specific lymphoid cell accumulation (Fig.  6a). 
In vivo homing in the absence of an EMF was first tested 
to determine whether MNP loading impaired T cell traf-
ficking towards SLOs. Irrespective of their origin (either 
the human T cell line Jurkat or primary murine T cells) 
MNP-loaded T cells were found in a higher number than 
MNP-free T cells in the collected peripheral and mes-
enteric LNs and in the spleen (Fig. 7b, c). This difference 
was more remarkable in the case of Jurkat cells (Fig. 7b), 
and at later timepoints (data not shown).
After verifying that MNP treatment did not impair T 
cell homing capacity, these experiments were repeated 
with an EMF applied to a popliteal LN to potentially 
enhance cell retention at this location. Flow cytom-
etry analyses after LN collection and disaggregation 
revealed that similar amounts of cells were found in pairs 
of matching lymph when no EMF was applied. EMF 
application increased the amount of cells found on the 
Fig. 5 Biological effects of MNP treatment of Jurkat and murine primary T cells. Overlays of representative histograms for cell surface markers 
of a Jurkat and b murine T cells after MNP treatment, compared to untreated cells. Isotype/unstained control, grey fill; untreated cells, blue line; 
MNP‑treated cells, orange line. Chemotactic response of c Jurkat and d murine T cells after treatment with MNPs. A mixture of differentially 
labelled MNP‑free and MNP‑loaded Jurkat or murine T cells (ratio 1:1) was prepared and seeded over a transwell. Their migration in the presence 
of chemotactic gradient of CXCL12 for Jurkat cells or CCL21 for T cells and in the presence or absence of a magnetic field was evaluated by flow 
cytometry after 16 h in Jurkat cells and 2 h in murine T cells. The results were normalized to input ratio. Data (mean ± SD) are representative of 
three‑four independent experiments. Student’s t‑test, *p < 0.05, **p < 0.01, ***p < 0.001
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popliteal LN where the magnet was applied (Fig. 7d, e). 
The slight increase also detected in MNP-free cells in the 
LN with EMF application was probably due to their inter-
action with MNP-treated cells in the cell mixture prior to 
injection, resulting in MNP transfer and/or aggregation 
of treated and untreated cells. Indeed, control inocula-
tions of MNP-free cells alone showed no differential 
increase of this cell population in the LN over which 
the EMF was applied (Fig.  7f ). Popliteal LNs were also 
imaged using SPIM. Image analysis revealed that larger 
numbers of transferred cells loaded with MNPs were 
retained in the LN exposed to a magnet than in non-
exposed one (Fig.  8). These results confirm the results 
obtained in our in vivo homing studies.
MNPs and EMFs reduced T cell speed in popliteal LNs
Once magnetic retention of MNP-loaded T cells in 
the LNs was confirmed, we also wanted to study T cell 
behaviour in  vivo and in real time. For this, intravital 
two-photon microscopy of popliteal LNs was performed 
in the absence of EMF or in EMF presence on one side 
or on both sides of the popliteal LN to increase mag-
netic field strength (Fig. 9a, b). A combination of MNP-
loaded and MNP-free cells (ratio 1:1) was inoculated just 
prior to recording and cell speed while traveling through 
the popliteal LN was analysed with the Imaris software. 
Image analysis from the recorded movies (Additional 
file  4: Movie S3; Additional file  5: Movie S4; Additional 
file  6: Movie S5) showed that MNP-loaded cells had a 
Fig. 6 In vitro retention of MNP‑loaded cells in flow chamber assays. a Experimental set‑up for determining the magnetic in vitro retention of 
MNP‑loaded cells. A special two‑magnet system was made to apply a homogeneous magnetic gradient and ibidi flow chambers were modified 
to adapt them to this device. b Summary of the properties of the permanent neodymium magnets used. Displacement in the magnetic 
force direction (Y‑axes) of MNP‑loaded c Jurkat and d murine primary T cells for varying MNP concentrations and magnetic force conditions. 
Cell displacement was analysed in at least 100 cells per movie by Imaris software. Data (mean ± SD) are representative of three independent 
experiments. Student’s t‑test, *p < 0.05, **p < 0.01, ***p < 0.001. e Capture of a flow chamber assay movie before and after magnetic field application. 
Arrows indicate the cell retention in the chamber wall near the magnet while applied
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10% reduction in their speed compared to MNP-free cells 
even in the absence of EMF (Fig. 9c, d). No preferential 
location or directionality was observed in these experi-
ments, even in the presence of an EMF (Additional file 1: 
Fig. S3). Image analysis nonetheless confirmed that the 
MNP-loaded T cells were better retained in the popliteal 
LN than MNP-free cells (Fig.  9d). EMF application fur-
ther reduced MNP-loaded T cell speed in the popliteal 
LN, and this was exacerbated by the application of 2 
EMF. Surprisingly the speed of MNP-free cells was also 
Fig. 7 In vivo homing capacity of Jurkat and murine primary T cells after MNP treatment with and without an EMF. a Experimental set‑up for 
determining the homing capacity of MNP‑loaded cells compared to MNP‑free cells. A mixture of differentially fluorescence‑labelled MNP‑free 
and MNP‑loaded Jurkat or murine T cells  (107 cells; ratio 1:1) was prepared and intravenously injected into nude (Jurkat) or C57BL/6J (murine T 
cells) recipient mice. After 1 h, peripheral (PLN) and mesenteric (MLN) LNs and spleen were collected, processed and analysed by flow cytometry. 
Homing capacity of MNP‑free and MNP‑loaded b Jurkat and c murine T cells in the absence of an EMF, 1 h after cell injection. Data (mean ± SD) are 
representative of three independent experiments (n = 6). Student’s t‑test, *p < 0.05, **p < 0.01, ***p < 0.001. Ratio of MNP‑free and MNP‑loaded d 
Jurkat and e murine T cells in the LN exposed to an EMF to control LN (no EMF), 20 min after intravenous injection of the cell mixture into recipient 
mice, normalized to the input ratio. f Ratio of MNP‑free murine T cells, administered alone as control, in the LN exposed to an EMF to control LN 
(no EMF) after intravenous injection. Ratios of cell homing in magnet LN to no magnet LN (mean ± SD) are representative of three independent 
experiments [n = 4 (Jurkat cells), n = 6 (murine T cells)]. Student’s t‑test, *p < 0.05, **p < 0.01, ***p < 0.001
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reduced in the popliteal LN when an EMF was applied 
(Fig. 9c, d). These could nonetheless be artefactual effects 
comparable to those detected in in vivo homing experi-
ments (Fig.  7d–f) due to MNP transfer from MNP-
loaded to MNP-free cells during inoculum preparation. 
It thus appears that MNP loading of T cells can promote 
cell retention in LNs and that circulation speed through 
the lymphoid organ can be reduced by EMF application.
Discussion
To evaluate the possibility of using MNPs to magneti-
cally direct or retain T cells to a region of interest, we 
synthesized and characterized MNPs with coatings that 
provide different surface charges, and we have stud-
ied their effects on T cell. The MNPs used in this study 
were produced by the coprecipitation method and had an 
average core diameter of 12.5 nm. FTIR spectra and DLS 
measurements confirmed coating procedure succeeded 
in creating monodispersed MNP preparations with dif-
ferent surface charges. MNP treatment did not cause 
any toxicity in the human T cell line Jurkat or in murine 
primary T cells in the conditions tested. MNP-treated 
murine primary T cells, however, presented a higher 
mitochondrial respiration and glycolysis. This could be 
associated with an activated state in T cells, since aero-
bic glycolysis increases during the transition to effector 
T cells. Moreover, glycolytic catabolism is also associated 
with T cell functionalities such as  Treg and memory T 
cells [36].
Microscopy analysis showed that unlike macrophages, 
mesenchymal or malignant cells, which are able to inter-
nalize different type of MNPs [11, 37–39], including the 
ones used in the present study (Additional file 1: Fig. S4) 
[40], T cells are apparently unable to do so. MNPs remain 
on the cell surface in close contact with cell membrane. 
T cells have typically low phagocytic capacity [41] with 
large nuclei and reduced cytoplasm, which could impair 
MNP entry inside the cytoplasm. Moreover, it has been 
also described that transfection of such cell types has 
always presented many difficulties and limitations, being 
Fig. 8 Distribution of MNP‑free and MNP‑loaded murine primary T cells in the popliteal LN in the absence or the presence of an EMF. a SPIM images 
of the popliteal LNs, 20 min after intravenous injection of a mixture of MNP‑free (yellow) and MNP‑loaded (green) murine T cells (ratio 1:1) into 
C57BL/6J recipient mice, exposed (right panel) or not (left panel) to an EMF. High endothelial venules (HEVs) are labelled in grey. b Quantification 
of the total transferred MNP‑free and MNP‑loaded murine T cells in SPIM images and the percentage of each cell type found in the absence or the 
presence of an EMF. Data are representative of 2 independent experiments
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a really inefficient process [42–46]. The low endocytic 
capacity of lymphoid cells has been already reported [47, 
48] and a special nanoparticle design is usually required 
to improve internalization by these nonphagocytic cells 
[49]. For example, some studies indicate that the uptake 
of NPs can be increased by coupling the NP to peptides 
or proteins, such as Tat protein of HIV, that exhibit a 
high permeability [50–52]. Microscopy analysis and cell-
associated iron quantification showed that APS-MNPs 
were the MNPs most associated with T cells and they 
were therefore selected to perform subsequent magnetic 
retention experiments. DMSA-MNPs and DEXT-MNPs 
have negative and neutral charges respectively, whereas 
APS-MNPs are positively charged which probably favour 
their interaction with the negative potential of the cell 
membrane. There is a general tendency to assume that 
positively charged nanoparticles interact further with 
cell membranes, possibly due to electrostatic interactions 
[53–60]. In this study, the positive MNPs (APS-MNPs) 
were the ones that interacted most with the membrane 
of the lymphoid cells, which correlates with what is 
described in the literature. Besides, some of the neutral 
and negative MNPs (DEXT- and DMSA-MNPs respec-
tively) also interact but with smaller areas of the cell sur-
face. This could be explained by the fact that, although 
cell membrane is, in general, negatively charged, it also 
presents areas with cationic sites allowing the binding of 
negatively charged NPs resulting in the clustering of the 
NPs around those domains [61].
Cytometric analyses of MNP-treated T cells showed 
that APS-MNPs caused no differences in the expres-
sion levels of important cell surface markers such as 
CD62L, CD44, CD11a or CCR7 in Jurkat and primary T 
cell. These data are in consonance with previous reports 
showing that MNPs have no significant effect on the 
expression levels of surface markers of a variety of cells 
Fig. 9 In vivo behaviour of MNP‑free and MNP‑loaded murine primary T cells in the popliteal LN in the absence or the presence of an EMF. a 
Experimental set‑up of the 2PM assays, showing the exposure of the popliteal LN to the different EMF conditions. b Capture of the 2PM movies 
after intravenous injection of a mixture of  107 cells, differentially labelled MNP‑free (blue) and MNP‑loaded (red) murine T cells into C57BL/6J 
recipient mice, in the absence of an EMF and in the presence of one or two magnets. HEVs are labelled in grey. c Quantification of cell speed in all 
conditions with Imaris software. Data (mean ± SD) are representative of two or three independent experiments. Student’s t‑test, *p < 0.05, **p < 0.01, 
***p < 0.001. d Summary of the analyses of 2PM movies. Ratio (%) of unloaded to MNP‑loaded cells and cell speed (mean ± SD) in the popliteal LN 
are representative of two or three independent experiments
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[62–66]. MNPs can trigger cellular activation in some 
cases [39, 67, 68] but this is mostly due to the nanoparti-
cle design [69].
Chemotaxis is critical to T cell biology as it guides T 
cell movement across tissues and to the regions where 
their activity is required. MNP loading slightly decreased 
chemotactic responses. Our data nonetheless indicate 
that the adequate application of an EMF could correct 
this defect, probably because the magnetic gradient facil-
itated the migration of these MNP-loaded cells. Similar 
results are reported in dendritic cells [12, 66], which indi-
cate that MNP loading of immune cells could affect their 
chemotaxis. One of the main concerns of the present 
study was to evaluate the capacity of a magnetic field to 
promote the retention of MNP-loaded T cells in the pres-
ence of flow forces similar to the ones found in blood ves-
sels. Our results showed that a minimal amount of MNPs 
was required for T cells to be retained by an EMF. This 
magnetic retention increases with the amount of MNPs 
associated to the cells as well as with the magnetic field 
magnitude. Other studies also reported that these two 
parameters are critical for this magnetic targeting to 
occur [70, 71].
The in  vivo analysis of T cell homing capacity in the 
presence or absence of MNPs revealed a higher amount 
of MNP-loaded T cells retained in the LNs, indicating 
that the presence of MNPs on the surface of T cells could 
increase by itself their retention in SLOs. MNP-loaded 
cells, however, did not show any preferential location or 
distribution for a specific SLO. The preferential accumu-
lation of MNP-loaded T cells in lymphoid tissues even 
in the absence of a magnetic field has the potential to 
favour T cell interactions with accessory cells in these 
organs where T cell activation occurs. This property 
of MNP-loaded T cells could be used to promote T cell 
responses to specific antigens as well as to modulate the 
immune response in a pathological context. For example, 
for therapies based on adoptive transfer of regulatory T 
cells (T regs), approaches enhancing the LN trafficking 
and retention of these T regs could be beneficial to pre-
vent immune-mediated diseases [72]. The strategic LN 
enrichment of antigen-specific T regs is crucial in con-
trolling autoreactive effector T cells (T effs) and autoim-
munity [73, 74]. For instance, it has been described that 
the accumulation of regulatory T cells in a LN near an 
ovary, counteracts the pathogenic immune response that 
takes place during ovarian autoimmune disease, inhib-
iting therefore its development [74]. Besides, there are 
studies showing that the recirculation of T regs in mes-
enteric LNs contributes to the downregulation of intes-
tinal inflammation [75], that their accumulation in the 
draining LN of the lung correlates with the resolution of 
chronic asthma in murine models [76] and also that the 
migration of T regs to specific draining LNs is required 
to suppress the alloimmune response [77] and is capa-
ble to induce suppression of arthritis [78]. Therefore, the 
modulation of T cell trafficking could have interest in 
the treatment of autoimmune diseases. This preferential 
accumulation of MNP-loaded T cells in lymphoid tis-
sues was also confirmed in the SPIM analyses of the LNs. 
There are some reports that analyse the biodistribution 
of MNP-labelled cells in different organs at short time 
points by magnetic resonance imaging [79–81]. Dodd 
et  al. showed that most of naïve and memory T cells 
migrated to the spleen and LNs but also to the lungs and 
liver after adoptive transfer [81]. It is also described that 
in a tumour model, MNP-labelled  CD8+ T cells accumu-
lated preferentially in the spleen and lymphoid tissues as 
well as in the tumour but also in the liver and in the lung 
[79, 80]. In this in vivo analysis, the application of an EMF 
favoured the retention of MNP-loaded transferred cells 
in the LN exposed to the magnet, indicating that, after 
reaching the LN, more MNP-loaded T cells were retained 
due to the presence of the EMF. Similar results have been 
obtained using other different cell types and regions of 
interest [12, 18, 38, 65, 66, 71, 82]. Our results reinforce 
the idea of magnetic targeting as a way to improve spe-
cific cell accumulation and extend its application to T 
lymphocytes, a relatively unexplored field.
Two-photon microscopy intravital in  vivo behaviour 
of MNP-loaded T cells in the popliteal LNs confirmed 
the increased retention of MNP-loaded T cells in lym-
phoid organs and revealed a 10% reduction in their speed 
compared to MNP-free T cells. The increased reten-
tion of MNP-loaded T cells in lymphoid organs even in 
the absence of EMF (Fig.  7b, c) could thus be due to a 
reduced circulating speed that would prolong cell inter-
action with lymphoid tissue vasculature and facilitate 
retention. Unexpectedly, the speed of both MNP-loaded 
and –free T cells was reduced when applying an EMF. 
This could be partly due to the interaction between 
loaded and unloaded cells in the mixture prior to inocu-
lation as previously demonstrated (Fig. 7d–f), resulting in 
the transfer of some MNPs to the unloaded T cells. Addi-
tionally, it has been previously described that cells associ-
ated with MNPs present a greater tendency to aggregate 
[83], so MNP-loaded cells could probably interact further 
with other surrounding cells, treated or not with MNPs. 
Alternatively, moderate static magnetic fields can influ-
ence biological systems, mostly due to alterations of the 
transmembrane ion flux and the membrane phospholip-
ids [84–86]. Preliminary calcium imaging assays did not 
Page 17 of 20Sanz‑Ortega et al. J Nanobiotechnol           (2019) 17:14 
show significant alterations in calcium fluxes, essential 
for T cell functionality, neither in the maximum response 
nor the time to achieve it, in the presence of MNP in the 
case of Jurkat cells (Additional file 1: Fig. S5a, c). Murine 
T cells, however, showed a decrease in both, the maxi-
mum response and the mean response after MNP load-
ing (Additional file 1: Fig. S5b, d). Further studies would 
be needed to confirm this finding and determine its bio-
logical significance. Biological effects supposedly depend 
more on the magnitude of the magnetic field gradient 
than on its strength [87]. This could explain the increased 
reduction in cell speed obtained in intravital experi-
ments when two magnets were placed over the popliteal 
LN. This reduced speed could also have some interest. 
It has been reported that the duration of the interaction 
between dendritic cells and T cells in the LNs affects the 
specificity and potency of the T cell responses [88–91]. 
The decrease in the speed of T cells in the LN could 
serve to favour their interaction with the dendritic cells 
and the generation of more powerful T cell responses 
with a greater affinity. Cell path analysis in these experi-
ments indicated that MNP loading does not influence 
the lymphocyte trajectory inside de LN when an EMF is 
applied, although further analysis over longer time peri-
ods and with increased EMF strength could be necessary 
to detect trajectory changes due to the complex tissue 
architecture of LN. Some of these effects could also be 
masked by MNP transfer to unloaded cells during inocu-
lum preparation.
Conclusions
T lymphocyte migration is a strongly regulated pro-
cess, essential in the development of potent and effec-
tive immune responses against different antigens. In the 
present study, we successfully show that the use of MNPs 
and EMFs can guide and retain T lymphocytes to a tar-
get region of interest without critically affecting crucial 
biological aspects of these cells. We demonstrate that 
MNP-loaded murine T cells can be magnetically retained 
in the LNs, which could be useful to modulate immune 
response in a pathological context. This strategy could 
potentially be applied to other regions of interest, such as 
a tumour, to enhance the antitumoral immune response 
led by activated T cells.
Thus, our study describes an interesting and affordable 
approach to promote T cell retention that could be imple-
mented in adoptive cell transfer therapies. This magnetic 
manipulation of T cell localisation could help improve 
their efficacy in autoimmunity and cancer treatment.
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